News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Noxopharm.
RELATED STOCKHEAD STORIES
News
In Case You Missed It: Orphan drug designation and air traffic control deals
News
ASX Small Caps Lunch Wrap: Who’s rooting for lower for longer today?
News
Market Highlights: Wall Street cops it on strong jobs but who cares when we’ve got all these lovely ASX lithium leads
News
Closing Bell: Bleak benchmark goes back to the beginning as Wall Street worries widen; RBA holds at 4.1pc
News
ASX Small Caps Lunch Wrap: Who’s just dying to make a bit of spare cash this week?
Health & Biotech
ASX Health Stocks: Anatara moves rapidly to Stage 2 in Phase 1/2 bowel syndrome trial
Health & Biotech
ASX Health Stocks: FDA approves Imugene’s Phase 1 trial; Noxopharm says it can fight skin disease
News
Market Highlights: FAANG stocks at one-year high, and will US Fed skip a meeting in June?
News
Top 10 at 10: ASX opens lower, Redstone rises on highest Cu grade ever at Tollu Copper Project
Health & Biotech
ASX Health Stocks: Noxopharm plunges 45pc after discontinuing Veyonda clinical trials
Health & Biotech
ASX Biotech Stocks: Noxopharm eyes new mRNA product with market forecast to hit US$128 billion by 2030
News
Market Highlights: Binance and CZ sued by the US; and 5 ASX small caps to watch on Tuesday
News
Market Highlights: ASX to snap winning streak, and 5 small caps to watch on Tuesday
News
Market Highlights: Wall Street’s selling spree, BoE and ECB’s 50bp gift, and 5 ASX small caps to watch on Friday
Health & Biotech
ASX Health Stocks: Avita makes crucial announcement on its pivotal RECELL trial, shares up 9pc
Health & Biotech
ASX Health Stocks: Biotron expands COVID-19 study in Thailand; Noxopharm, Clarity progress pancreatic cancer research
News